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Aims High-density lipoprotein (HDL) cholesterol is a strong predictor of cardiovascular mortality. This work aimed to inves-
tigate whether the presence of coronary artery disease (CAD) impacts on its predictive value.
Methods
and results
We studied 3141 participants (2191 males, 950 females) of the LUdwigshafen RIsk and Cardiovascular health (LURIC)
study. They had a mean+ standard deviation age of 62.6+ 10.6 years, body mass index of 27.5+4.1 kg/m2, and
HDL cholesterol of 38.9+10.8 mg/dL. The cohort consisted of 699 people without CAD, 1515 patients with stable
CAD, and 927 patients with unstable CAD. The participants were prospectively followed for cardiovascular mortality
over a median (inter-quartile range) period of 9.9 (8.7–10.7) years. A total of 590 participants died from cardiovascular
diseases. High-density lipoprotein cholesterol by tertiles was inversely related to cardiovascular mortality in the entire
cohort (P ¼ 0.009). There was significant interaction between HDL cholesterol and CAD in predicting the outcome
(P ¼ 0.007). In stratified analyses, HDL cholesterol was strongly associated with cardiovascular mortality in people
without CAD [3rd vs. 1st tertile: HR (95% CI) ¼ 0.37 (0.18–0.74), P ¼ 0.005], but not in patients with stable [3rd vs.
1st tertile: HR (95% CI) ¼ 0.81 (0.61–1.09), P ¼ 0.159] and unstable [3rd vs. 1st tertile: HR (95% CI) ¼ 0.91 (0.59–
1.41), P ¼ 0.675] CAD. These results were replicated by analyses in 3413 participants of the AtheroGene cohort and
5738 participants of the ESTHER cohort, and by a meta-analysis comprising all three cohorts.
Conclusion The inverse relationship of HDL cholesterol with cardiovascular mortality is weakened in patients with CAD. The
usefulness of considering HDL cholesterol for cardiovascular risk stratification seems limited in such patients.
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Introduction
Epidemiological data have provided broad evidence that low concen-
trations of high-density lipoprotein (HDL) cholesterol indicate
increased cardiovascular risk.1–4 Although less consistently,5 this
relationship is even apparent in patients treated with statins.6 There-
fore, raising HDL cholesterol has become a therapeutic target in
coronary artery disease (CAD).7
Inhibition of cholesterol-ester transfer protein (CETP) is asso-
ciated with a substantial increase of HDL cholesterol.8–12
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Nevertheless, the use of torcetrapib did not improve but rather wor-
sened prognosis in the ILLUMINATE trial.11 Treatment with dalcetra-
pib did not reduce the risk of cardiovascular events in the recently
published dal-OUTCOMES trial either.12 These disappointing results
may in part be attributed to off-target effects of CETP inhibitors,
most importantly an increase in systolic blood pressure and
pro-inflammatory activity.11,12 An alternative explanation would be
that raising HDL cholesterol is less beneficial in certain subgroups,
for example, in patients with CAD. Notably, ILLUMINATE included
patients at high cardiovascular risk and all participants of the
dal-OUTCOMES trial had suffered a recent acute coronary syn-
drome.11,12
Therefore, the aim of the present study was to investigate whether
CAD at baseline affects the prognostic value of HDL cholesterol for
cardiovascular mortality. The exploratory analyses were performed
in the ‘LUdwigshafen RIsk and Cardiovascular health’ (LURIC)
cohort.13,14 Replication of the findings obtained from LURIC was
sought in the AtheroGene15,16 and the ESTHER17,18 cohorts. Consid-
ering that their clinical presentation, treatment, and prognosis differ
markedly, stable and unstable CAD were analysed separately.
Methods
Study design, participants, and clinical
characterization
LURIC
A total of 3316 patients, who were referred for coronary angiography to
the Ludwigshafen Heart Center in Southwest Germany, were recruited
between July 1997 and January 2000.13 Inclusion criteria were German
ancestry, clinical stability except for acute coronary syndromes, and the
availability of a coronary angiogram. The indications for angiography in
individuals in clinically stable condition were chest pain and/or non-
invasive test results consistent with myocardial ischaemia. Individuals
suffering from any acute illness other than acute coronary syndromes,
chronic non-cardiac diseases, or malignancy within the 5 past years,
and those unable to understand the purpose of the study were excluded.
Subjects with missing information on the clinical presentation of CAD,
missing laboratory measurements, or missing information on the cause
of death were additionally ruled out, resulting in a subgroup of 3141 par-
ticipants for the present analyses. Coronary artery disease was diagnosed
if coronary angiography revealed stenosis of one or more vessels ≥20%.
Unstable angina was diagnosed according to Braunwald. Acute myocar-
dial infarction was defined as a myocardial infarction that had occurred
within the 4 weeks prior to enrolment into LURIC. A definite
ST-elevation myocardial infarction was diagnosed if typical electrocar-
diogram changes were present along with prolonged chest pain, refrac-
tory to sublingual nitrates, and/or enzyme or troponin T elevations
(.0.1 g/L). Non-ST-elevation myocardial infarction was diagnosed if
symptoms and troponin T criteria but not the ECG criteria for
ST-elevation myocardial infarction were met.13 The functional capacity
of patients with cardiac disease, especially heart failure, was estimated
according to a classification developed by the New York Heart
Association (NYHA).13 Left ventricular function was estimated using
echocardiography.13
AtheroGene
A total of 3800 patients, who underwent coronary angiography at the
Department of Medicine II of the Johannes Gutenberg-University
Mainz or the Bundeswehr-Zentralkrankenhaus Koblenz, were recruited
between June 1999 and March 2000.15,16 The exclusion criteria were evi-
dence of haemodynamically significant valvular heart disease, surgery or
trauma within the previous month, known cardiomyopathy, known
cancer, febrile conditions, or use of oral anticoagulant therapy within
the previous 4 weeks.15,16 Subjects with missing information on the clin-
ical presentation of CAD, missing laboratory measurements, or missing
information on the cause of death were additionally ruled out, resulting
in a subgroup of 3413 participants for the present analyses. Coronary
artery disease was diagnosed if the coronary angiogram showed at least
one stenosis.30% in a major coronary artery. Unstable angina was diag-
nosed according to Braunwald. Acute myocardial infarction was either
ST-segment elevation with significant elevation in at least two contiguous
leads or non-ST-elevation myocardial infarction based on clinic and
positive in-house troponin concentrations.16
ESTHER
A total of 9949 subjects were recruited for the ‘Epidemiologische Studie
zu Chancen der Verhu¨tung, Fru¨herkennung und optimierten Therapie
chronischer Erkrankungen in der a¨lteren Bevo¨lkerung (German)’ by
their general practitioners during a routine health check-up between
2000 and 2002 in the German federal state Saarland.17,18 The distribu-
tion of socio-demographic baseline characteristics and common preva-
lent chronic diseases were similar to the distribution in the respective
age categories in the German National Health Survey, which is a repre-
sentative sample of the German population,17 a fact supporting the
population-based character of the study. We excluded study partici-
pants due to unmeasured HDL cholesterol, due to an unknown cause
of death, and due to self-reported history of CAD that was not
physician-confirmed, leaving a subgroup of 5738 participants for the
present analysis. Coronary artery disease was defined by physician-
reported CAD.17,18
Ethical approval and written informed consent
All three studies were approved by the local ethics committees and per-
formed in accordance with the Declaration of Helsinki. All participants
gave written informed consent.13–18
Follow-up
In the LURIC cohort, there was a follow-up for cardiovascular mortality
with a mean+ standard deviation duration of 8.9+3.0 years (median
and inter-quartile range: 9.9, 8.7–10.7). Information on the vital status
was obtained from local person registries. Using death certificates, two
experienced clinicians independently classified the causes of death.
They were masked to any other data of the study participants. In a few
cases of a disagreement or uncertainty concerning the coding of a specific
cause of death, classification was made by a principal investigator of the
LURIC study (W.M.).13 In the AtheroGene cohort, there was a follow-up
for cardiovascular mortality with a mean+ standard deviation duration
of 4.5+ 2.0 years (median and inter-quartile range: 4.4, 2.9–6.3). Infor-
mation about the causes of death and clinical events was obtained from
hospital and general practitioner charts. In the ESTHER cohort, there
was a follow-up for cardiovascular mortality with a mean+ standard de-
viation duration of 9.1+ 1.6 years (median and inter-quartile range: 9.4,
8.9–9.9). Deaths were identified by inquiry at the residents’ registration
offices. All deaths coded with ICD-10 codes I00-I99 were considered to
be cardiovascular deaths.
Laboratory analyses
All analyses were performed in fasting blood samples. In the LURIC and
AtheroGene cohorts, the blood samples were collected before
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angiography.13 –16 In the ESTHER cohort, the blood samples were taken
during the health check-up.17,18
In the LURIC cohort, the lipoproteins were separated using a com-
bined ultracentrifugation–precipitation method (b-quantification).13
Cholesterol was measured with enzymatic reagents from WAKO
(Neuss, Germany) on a WAKO 30 R or Olympus AU640 (Tokyo,
Japan) analyser.13 Triglycerides were quantified with an enzymatic
colour assay on a Hitachi 717 analyser (Roche, Mannheim, Germany).13
Apolipoproteins A1, A2, and B were measured by turbidimetry (Rolf-
Greiner Biochemica, Flacht, Germany).13 In the AtheroGene cohort,
total cholesterol and triglycerides were measured enzymatically
(Roche Diagnostics, Mannheim, Germany). High-density lipoprotein
cholesterol was measured after masking apolipoprotein B immunologic-
ally (Rolf Greiner Biochemica, Flacht, Germany). LDL cholesterol was
calculated using the Friedewald formula.15,16 In the ESTHER cohort,
total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides
were measured with standard methods.17,18
Statistical analysis
Tertiles of HDL cholesterol were formed in each cohort. The baseline
characteristics are presented as counts and percentages of subjects in
cases of categorical data and as means and standard deviations or
medians with inter-quartile ranges in cases of continuous data for the
tertiles of HDL cholesterol. The x2 test and ANalysis Of VAriance
were used to compare the distributions of the variables across the ter-
tiles of HDL cholesterol. Triglycerides (Shapiro–Wilk W test) were
transformed logarithmically before being used in parametric statistical
procedures. The Cox proportional hazards model was used to
examine the association between HDL cholesterol and time to cardio-
vascular death. For exploratory purposes, the associations of the HDL
cholesterol tertiles with cardiovascular mortality were first studied in
the entire LURIC cohort. Two pre-defined models of adjustment were
used [model 1: adjusted for sex, age, and CAD; model 2: adjusted for
sex, age, body mass index, systolic and diastolic blood pressure,
diabetes mellitus, smoking, glomerular filtration rate, triglycerides,
low-density lipoprotein cholesterol, medication use (insulin, oral anti-
diabetic, b-blocker, ACE-inhibitor, calcium antagonist, diuretic, acetyl
salicylic acid, and statin), and CAD]. Moreover, the interaction
between the HDL cholesterol tertiles and CAD with regard to cardio-
vascular mortality was studied by including the interaction term as a
covariate. In the next step, stratified analyses in people without
CAD, in patients with stable CAD, and in patients with unstable
CAD were conducted using the aforementioned models of adjust-
ment. For replication, the associations of the HDL cholesterol tertiles
with cardiovascular mortality were studied in the AtheroGene and
ESTHER cohorts, which were stratified accordingly. All statistical
tests were two-sided and P-values ,0.05 were considered significant.
The SPSS 19.0 statistical package (SPSS, Inc., Chicago, IL, USA) was used
in the LURIC and ESTHER cohorts. The R statistical software package
(http://www.r-project.org) was used in the AtheroGene cohort. For
meta-analyses of the results obtained from the LURIC, AtheroGene,
and ESTHER cohorts, HRs were pooled by the inverse of the variance
method in a fixed effects model with the Comprehensive
Meta-Analysisw software.
Role of the funding source
The funding source was not involved in study design, in the collection,
analysis, and interpretation of data, in the writing of the report, and in
the decision to submit the paper for publication.
Results
LURIC
Baseline characteristics
The study participants (2191 males, 950 females) had a mean+
standard deviation age of 62.6+10.6 years, body mass index of
27.5+ 4.1 kg/m2, and HDL cholesterol of 38.9+10.8 mg/dL. High
HDL cholesterol was associated with female gender, lower body
mass index and waist circumference, and lower proportion of sub-
jects with diabetes mellitus (Table 1). High-density lipoprotein chol-
esterol was positively related to total, low-density lipoprotein, and
very low density lipoprotein cholesterol and inversely related to tri-
glycerides (Table 1). Furthermore, HDL cholesterol was positively
related to apolipoprotein A1, apolipoprotein A2, and inversely to
apolipoprotein B (Table 1). Prevalent stable and unstable CAD, cere-
bral vascular disease, and peripheral vascular disease were more fre-
quent in people with low HDL cholesterol (Table 1). Moreover, low
HDL cholesterol went in parallel with impaired left ventricular func-
tion (Table 1). Use of insulin, oral antidiabetics, b-blockers, ACE-
inhibitors, diuretics, statins, and acetyl salicylic acid were more
frequent in subjects with low HDL cholesterol (Table 1). The baseline
characteristics stratified for patients without CAD, patients with
stable CAD, and those with unstable CAD are shown in Supplemen-
tary material online, Table S1. There were no major differences in
the mean HDL cholesterol concentrations among the correspond-
ing HDL cholesterol tertiles of the subgroups without CAD, with
stable CAD, and with unstable CAD (Supplementary material
online, Table S1).
Prospective analyses
A total of 925 deaths occurred during the follow-up. Among these,
590 were due to cardiovascular diseases. In the entire cohort, the
HDL cholesterol tertiles were inversely related to cardiovascular
mortality (P ¼ 0.009) (Table 2). Further, investigations disclosed
significant interaction between the HDL cholesterol tertiles and
CAD with regard to cardiovascular mortality in model 1 (P ¼
0.146 and P ¼ 0.004 for 2nd and 3rd tertile vs. 1st tertile, respect-
ively) and in model 2 (P ¼ 0.178 and P ¼ 0.007 for 2nd and 3rd
tertile vs. 1st tertile, respectively). Subsequent analyses were,
therefore, stratified by the presence of CAD. By doing so, the ter-
tiles of HDL cholesterol were strongly associated with cardiovascu-
lar mortality in participants without CAD (P ¼ 0.005), but not in
participants with stable (P ¼ 0.162) or unstable (P ¼ 0.675) CAD
(Table 3). When we independently formed the HDL cholesterol
tertiles within the subgroups resulting in similar numbers of partici-
pants for the three tertiles, the associations of the HDL cholesterol
tertiles with cardiovascular mortality still remained significant in
participants without CAD, but not in participants with stable and
unstable CAD (data not shown).
AtheroGene
Baseline characteristics
The study participants (2568 males, 845 females) had a mean+
standard deviation age of 61.8+ 10.0 years, body mass index of
27.5+ 3.9 kg/m2, and HDL cholesterol of 49.2+ 14.6 mg/dL.
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Table 1 Baseline characteristics according to tertiles of high-density lipoprotein cholesterol in the LURIC cohort
Number 1st tertile 2nd tertile 3rd tertile P-valuee
1048 1083 1010
Male sex 868 (82.8) 776 (71.7) 547 (54.2) ,0.001
Age, years 61.8+11.1 62.6+10.2 63.6+10.4 0.001
Body mass index, kg/m2 28.1+4.1 27.8+4.1 26.6+3.9 ,0.001
Waist circumferencea, cm 101+11 100+11 96+12 ,0.001
Hypertension 767 (73.2) 798 (73.7) 732 (72.5) 0.822
Systolic blood pressure, mmHg 139+24 142+23 143+23 0.001
Diastolic blood pressure, mmHg 80+12 82+11 82+11 ,0.001
Diabetes mellitus 510 (48.7) 438 (40.4) 293 (29.0) ,0.001
Smoking ,0.001
Never 285 (27.2) 383 (35.4) 468 (46.3)
Former smoker 504 (48.1) 492 (45.4) 410 (40.6)
Current smoker 259 (24.7) 208 (19.2) 132 (13.1)
Lipidsb, mg/dL
Total cholesterol 182+41 194+37 203+36 ,0.001
LDL cholesterol 106+35 120+33 124+33 ,0.001
HDL cholesterol 28+4 38+3 51+8 ,0.001
VLDL cholesterol 46+33 37+24 28+18 ,0.001
Triglycerides 173 (128–241) 149 (114–201) 122 (93–161) ,0.001c
Apolipoprotein A1 108+15 128+13 155+19 ,0.001
Apolipoprotein A2 36+8 42+8 48+9 ,0.001
Apolipotrotein B 106+26 106+24 101+23 ,0.001
GFR, mL/min/1.73 m2 80+20 83+19 81+18 0.022
CAD ,0.001
No CAD 142 (13.5) 233 (21.5) 324 (32.1)
Stable CAD 509 (48.6) 535 (49.4) 471 (46.6)
Unstable CAD 397 (37.9) 315 (29.1) 215 (21.3)
Presentation of unstable CAD ,0.001
Unstable angina 223 (21.3) 217 (20.0) 181 (17.9)
NSTEMI 61 (5.8) 34 (3.1) 19 (1.9)
STEMI 113 (10.8) 64 (5.9) 15 (1.5)
NYHA functional class 0.339
1 527 (50.3) 569 (52.5) 509 (50.4)
2 302 (28.8) 319 (29.5) 314 (31.1)
3 189 (18.0) 157 (14.5) 157 (15.5)
4 30 (2.9) 38 (3.5) 30 (3.0)
Left ventricular function (echo)d ,0.001
Normal 542 (53.1) 665 (62.9) 723 (72.7)
Mildly impaired 163 (16.0) 155 (14.7) 116 (11.7)
Moderately impaired 136 (13.3) 123 (11.6) 76 (7.6)
Severely impaired 77 (7.5) 36 (3.4) 28 (2.8)
Peripheral vascular disease 147 (14.0) 86 (7.9) 66 (6.5) ,0.001
Cerebrovascular disease 123 (11.7) 87 (8.0) 76 (7.5) 0.001
Medication use
Insulin 70 (6.7) 59 (5.4) 38 (3.8) 0.013
Oral antidiabetic 125 (11.9) 84 (7.8) 46 (4.6) ,0.001
b-Blocker 730 (69.7) 697 (64.4) 552 (54.7) ,0.001
Continued
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The baseline characteristics of the AtheroGene cohort stratified for
patients without CAD, patients with stable CAD, and those
with unstable CAD are shown in Supplementary material online,
Table S2.
Prospective analyses
A total of 381 deaths occurred during the follow-up. Among these,
264 were due to cardiovascular diseases. Low HDL cholesterol
was strongly associated with increased cardiovascular mortality in
people without CAD (Table 4). The association between HDL chol-
esterol and cardiovascular mortality was less pronounced in patients
with stable CAD and turned non-significant after multivariate adjust-
ment (Table 4). In patients with unstable CAD, there was no signifi-
cant association between the tertiles of HDL cholesterol and
cardiovascular mortality (Table 4).
ESTHER
Baseline characteristics
The study participants (2606 males, 3132 females) had a mean+
standard deviation age of 62.0+6.6 years, body mass index of
27.7+ 4.3 kg/m2, and HDL cholesterol of 53.5+ 15.3 mg/dL. The
baseline characteristics of the ESTHER cohort stratified for people
withoutCADandpatientswith stable CADareshown in Supplemen-
tary material online, Table S3.
Prospective analyses
A total of 586 deaths occurred during the follow-up. Among these,
196 deaths were due to cardiovascular diseases. High-density lipo-
protein cholesterol was inversely related to cardiovascular mortality
in people without CAD (Table 4). This association reached statistical
significance comparing the 2nd with the 1st tertile of HDL choles-
terol (Table 4). In patients with stable CAD, there was no significant
associationbetweenthe tertilesof HDLcholesterol andcardiovascu-
lar mortality (Table 4).
Meta-analysis
The meta-analysis comprised 12 292 participants of the LURIC,
AtheroGene, and ESTHER cohorts. In the subgroup of 5791 people
without CAD, the HDL cholesterol tertiles were significantly, in-
versely related to cardiovascular mortality (Table 5). In contrast,
the HDL cholesterol tertiles were not significantly related to cardio-
vascular mortality in the 4304 patients with stable CAD and the 2197
patients with unstable CAD (Table 5).
Discussion
The present data from a total of 12 292 participants of the LURIC, the
AtheroGene, and the ESTHER cohorts show that CAD modulates
the association of HDL cholesterol with cardiovascular mortality.
High-density lipoprotein cholesterol tertiles were significantly
inversely related to cardiovascular mortality in the entire LURIC
cohort. Inclusion of the interaction term between CAD and HDL
cholesterol indicated variation in the predictive value of HDL choles-
terol for cardiovascular mortality according to the presence of CAD.
In stratified analyses, the association between the HDL cholesterol
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Continued
Number 1st tertile 2nd tertile 3rd tertile P-valuee
1048 1083 1010
ACE-inhibitor 637 (60.8) 565 (52.2) 455 (45.0) ,0.001
Calcium antagonist 156 (14.9) 169 (15.6) 174 (17.2) 0.331
Diuretic 366 (34.9) 286 (26.4) 244 (24.2) ,0.001
Statin 576 (54.9) 530 (48.9) 408 (40.4) ,0.001
Acetyl salicylic acid 790 (75.4) 773 (71.4) 672 (66.5) ,0.001
Values are means+ standard deviations or medians (25th–75th percentiles) in cases of continuous variables and numbers (percentages) in case of categorical data.
aNumbers: 1035/1073/994.
bToconvert values for total, LDL, HDL, and VLDL cholesterol to millimoles per litre, multiply by 0.02586; to convert values for triglycerides to millimoles per litre, multiply by 0.01129.
cANalysis Of VAriance of logarithmically transformed values.
dNumbers: 918/979/943.
eFor differences across the three groups calculated with x2 test and ANalysis Of VAriance for categorical and continuous data, respectively.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Cardiovascular mortality according to tertile
of high-density lipoprotein cholesterol in the LURIC
cohort
n CD HR P-value
Model 1a
1st tertile 1048 248 (23.7) 1.0 reference
2nd tertile 1083 190 (17.5) 0.71 (0.59–0.86) ,0.001
3rd tertile 1010 152 (15.0) 0.59(0.36–0.80) ,0.001
Model 2b
1st tertile 1048 248 (23.7) 1.0 reference
2nd tertile 1083 190 (17.5) 0.82 (0.67–1.00) 0.052
3rd tertile 1010 152 (15.0) 0.74 (0.59–0.93) 0.009
n, number; CD, number of cardiovascular deaths (percentage of tertile); HR, hazard
ratio (calculated with Cox proportional hazards model).
aAdjusted for sex, age, and CAD.
bAdjusted for sex, age, body mass index, systolic and diastolic blood pressure,
diabetes, smoking, glomerular filtration rate, triglycerides, LDL cholesterol,
medication use (insulin, oral antidiabetic, b-blocker, ACE-inhibitor, calcium
antagonist, diuretic, acetyl salicylic acid, and statin), and CAD.
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tertiles and cardiovascular mortality was strong in people without
CAD, whereas it was weak and non-significant after multivariate ad-
justment in patients with stable and unstable CAD. Very similar
observations were made in the AtheroGene cohort. The aforemen-
tioned differences were less pronounced in the ESTHERcohort, pos-
sibly due to the lack of coronary angiograms and consequently a large
proportion of undiagnosed, silent CAD. Finally, a meta-analysis com-
prising all three cohorts was performed and the results were in
support of the LURIC findings.
Previous studies have not specifically addressed an interaction of
HDL with CAD, probably because very few studies have collected
precise information on both, CAD at baseline and cardiovascular
death. However, our results are in agreement with evidence from
the dal-OUTCOMES trial.12 In this cohort of 15 871 patients, who
had suffered acute coronary syndromes, HDL cholesterol was not
predictive of the primary endpoint.12 Moreover, the present obser-
vations are confirmed by recent data on the cholesterol efflux cap-
acity from macrophages to serum, which is positively related to
HDL cholesterol.19,20 In cross-sectional analyses, low cholesterol
efflux capacity was repeatedly associated with higher prevalence of
CAD.19,20 At the same time, the cholesterol efflux capacity was posi-
tively associated with the risk of future vascular complications in
patients with CAD, whereas no such paradox association was seen
in an outpatient cohort.20
Two potential reasons that may explain the interaction between
the HDL cholesterol tertiles and CAD with regard to cardiovascular
mortality shall be highlighted: first, dysfunctional HDL may account
for weakerassociations of HDL cholesterolwith cardiovascular mor-
tality in CAD. High-density lipoprotein is considered to represent the
major vehicle of reverse cholesterol transport.21–23 In addition, HDL
may exert anti-inflammatory effects, prevent low-density lipoprotein
oxidation, and play an important role in nitric oxide synthesis.21– 23
Even anti-thrombotic potency has been suggested.21–23 Neverthe-
less, there is growing knowledge that the vascular protective proper-
ties of HDL are impaired in certain diseases.24,25 Most importantly,
the anti-inflammatory and anti-oxidative effects of HDL were
demonstrated to be reduced in CAD.26,27 In the LURIC cohort,
the apolipoprotein A1 and A2 composition of HDL did not explain
the key finding (Supplementary material online). Future studies
within the LURIC cohort will address other aspects of HDL function-
ality. Second, multimodal treatment of cardiovascular risk factors and
co-morbidity may have blunted the relationships of HDL cholesterol
with cardiovascular mortality in patients with CAD. However,
exploratory analyses within the LURIC cohort did not support this
possibility (Supplementary material online).
It is a limitation of our study that HDL cholesterol was measured
once at baseline only. Therefore, we were not able to adjust for pos-
sible moderate fluctuations of HDL cholesterol during the follow-up,
for example due to the start of statin treatment or an increase of the
statin dose.28 The major strength of this work is the detailed clinical
and metabolic investigation of the LURIC participants, including
coronary angiography. Moreover, we want to emphasize the long
duration of the follow-up with a large number of fatal cardiovascular
events. In addition, our conclusions rely on replication in 3413 parti-
cipants of the AtheroGene cohort and 5738 participants of the
ESTHER cohort, and on a meta-analysis comprising all three cohorts.
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Table 4 Cardiovascular mortality according to tertiles of high-density lipoprotein cholesterol stratified for coronary artery disease in the ESTHER and AtheroGene
cohorts
No CAD Stable CAD Unstable CAD
n CD HR P-value n CD HR P-value n CD HR P-value
AtheroGene
Model 1a
1st tertile 35 6 (17.1) 1.0 reference 674 65 (9.6) 1.0 reference 509 46 (9.0) 1.0 reference
2nd tertile 45 2 (4.4) 0.29 (0.06–1.44) 0.128 643 39 (6.1) 0.65 (0.43–0.96) 0.031 421 36 (8.6) 0.95 (0.62–1.48) 0.828
3rd tertile 73 2 (2.7) 0.16 (0.03–0.82) 0.027 673 42 (6.2) 0.57 (0.38–0.86) 0.007 340 26 (7.6) 0.68 (0.42–1.12) 0.127
Model 2b
1st tertile n.a.c n.a.c n.a.c n.a.c 663 65 (9.8) 1.0 reference 503 45 (8.9) 1.0 reference
2nd tertile 633 38 (6.0) 0.88 (0.58–1.33) 0.539 416 36 (8.7) 1.06 (0.67–1.69) 0.792
3rd tertile 659 41 (6.2) 0.73 (0.47–1.13) 0.159 337 26 (7.7) 0.90 (0.53–1.52) 0.685
ESTHER
Model 1a
1st tertile 1546 47 (3.0) 1.0 reference 362 37 (10.2) 1.0 reference n.a.d n.a.d n.a.d n.a.d
2nd tertile 1665 29 (1.7) 0.58 (0.36–0.92) 0.020 255 29 (11.4) 1.18 (0.72–1.93) 0.502
3rd tertile 1728 35 (2.0) 0.74 (0.46–1.17) 0.199 182 19 (10.4) 1.14 (0.64–2.02) 0.659
Model 2b
1st tertile 1184 37 (3.1) 1.0 reference 282 26 (9.2) 1.0 reference
2nd tertile 1324 23 (1.7) 0.58 (0.34–1.00) 0.050 211 24 (11.4) 1.80 (0.98–3.33) 0.059
3rd tertile 1410 29 (2.1) 0.80 (0.50–1.27) 0.226 151 14 (9.3) 1.70 (0.80–3.61) 0.168
n, number; CD, number of cardiovascular deaths (percentage of tertile); HR, hazard ratio.
aAdjusted for sex and age.
bAdjusted for sex, age, body mass index, systolic and diastolic blood pressure (hypertension in the AtheroGene cohort), diabetes, smoking, glomerular filtration rate, triglycerides, LDL cholesterol, and medication use (insulin, oral antidiabetic,
b-blocker, ACE-inhibitor, calcium antagonist, diuretic, acetyl salicylic acid, and statin).
cSample size too low.
dNo patients with unstable CAD in this cohort.
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To sum up, the association of HDL cholesterol with cardiovascular
mortality is weakened in the presence of CAD. The usefulness of
considering HDL cholesterol for cardiovascular risk stratification
may be limited in secondary prevention.
Supplementary material
Supplementary material is available at European Heart Journal online.
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